We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
The SARS-CoV T-cell peptide antigens set contains 5 peptides corresponding to SARS-CoV spike protein sequence. The sequences have been tested for HLA binding with SARS-CoV protein and includes a positive and a negative control. CV1, CV2 and CV3 sequences are also seen within the spike glycoprotein of SARS-CoV2. The peptide sequences are offered in net peptide quantities in individual vials of 0.25 mg each. The peptide epitopes can be used in ELISPOT, cytokine and CTL assays. The sequences in the set are, CV1- VLNDILSRL CV2- NLNESLIDL CV3- FIAGLIAIV CV4- KLPDDFMGCV (+ve control) CV5- AYRPPNAPIL (-ve control)
Peptide Library Construction and Screening
Powerful screening tools in biological and chemical research
Size | 0.25 mg NET peptide |
References | 1. Lv Y, et al. Identification of a novel conserved HLA-A* 0201-restricted epitope from the spike protein of SARS-CoV. BMC immunology. 2009 Dec 1;10(1):61.2. Ahmed SF et al. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020 Mar;12(3):254. |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com